Drug-abuse deterrent formulations

Consultant Pharmacist

Volumn 24, Issue 5, 2009, Pages 356-365

  Wick, Jeannette Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Abuse deterrent formulation; Drug abuse; Drug formulation; Drug Misuse; Prescription drug abuse; Prodrug

Indexed keywords

DIAMORPHINE; FENTANYL; MORPHINE SULFATE; NALOXONE; OPIATE; OXYCODONE; PENTAZOCINE; PRODRUG; TRIPELENNAMINE;

ABUSE DETERRENT FORMULATION; DRUG ABUSE; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; PRESCRIPTION; REVIEW; RISK ASSESSMENT; UNITED STATES;

EID: 66749085604     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.356     Document Type: Review

References (24)

1. Schanlaub R. A prescription for abuse. Law & Order 2003;51:93-4.
2. Substance Abuse and Mental Health Administration. Non-Medical Use and Abuse: Prescription-type and Over-the-Counter Drugs. Available at http://www.oas.samhsa.gov/prescription.htm. Accessed December 1, 2008.
3. Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006;83 Suppl 1:31-39.
4. Inciardi JA, Surratt HL, Kurtz SP et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8:171-83.
5. Katz NP, Adams EH, Chilcoat H et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-60.
6. Marquardt KA,Tharratt RS, Musallam NA. Fcntanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995;29:969-71.
7. Flannagan LM, Butts JD, AndersonWH. Fentanyl patches left on dead bodies-potential source of drug for abusers. J Forensic Sci 1996;41:320-1.
8. Davis M. Caregiver accused of stealing pain medicine; Daily Edition White River Junction, VT: November 14, 2007:A. 1
9. DeardorffJ. Internet ODs with know-how for drug abusers. Washington, DC: Knight Ridder Tribune News Service; July 7, 2006:1.
10. U.S. Department of Justice, National Drug Intelligence Center. National Drug Threat Assessment. 2009. Available at http://www.usdoj.gov/ndic/pubs31/ 31379/31379p.pdf. Accessed December 15, 2008.
11. Center on Addiction and Substance Abuse at Columbia University, 2005. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S., July.
12. McCormick CG. Regulatory challenges for new formulations of controlled substances in today's environment. Drug Alcohol Depend 2006;83 Suppl 1:63-67.
13. Sapienza FL. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend 2006;83 Suppl 1:23-30.
14. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10:11-8.
15. McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006; 83 Suppl 1:52-62.
16. Grudzinskas C, Balster RL, Gorodetzky CW et al. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend 2006;83 Suppl 1:77-82.
17. Katz NP, Adams EH, Benneyan JC et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18.
18. Sunshine A, Axtmayer R, Olson N et al. Analgesic efficacy of pentazocine versus a pentazocine-naloxone combination following oral administration. Clin J Pain 1988;4:35-40.
19. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987;102:426-9.
20. Reed DA, Schnoll SH. Abuse of pentazocine-naloxone combination. JAMA 1986;256:2562-4.
21. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2005: National estimates of drug-related emergency department visits. DAWN Series D-29, DHHS Publication No. SMA 07-4256. Rockville, MD: Department of Health and Human Services; 2007.
22. Passik SD, Kirsh KL, Donaghy KB et al. Pain and aberrant drug-related-behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22:173-81.
23. Ciccone PE. Attempted abuse of Concerta. J Am Acad Child Adolesc Psychiatry 2002; 41:756.
24. Jaffe SL. Failed attempts at intranasal abuse of Concerta. J Am Acad Child Adolesc Psychiatry 2002;41:5.